LOW COST HIV DRUG RESISTANCE MONITORING

描述：(改编自申请者摘要)耐药性是唯一的 缺乏艾滋病毒控制的最大原因。病毒的定量检测 负荷和耐药性可以提供必要的信息，合理地 修改药物疗法。病毒载量的增加可能是由于 患者的免疫状态或病毒的毒力或缺乏 患者依从性差，用药安排困难。治疗以下患者： 可能感染了一种与联合用药有关的抗药性病毒 治疗可能对病人有害。知道一种药物的确切性质 耐药突变也可以用来预测交叉耐药或减少 对其他药物的抗药性。这项工作将开发RT-PCR条件，引物， 捕获序列和进行定量检测的内部标准 野生型和抗药性艾滋病毒是一个简单而快速的过程，即使在 适应在病毒中发现的已知序列多态。在此阶段 二、常见逆转录酶检测方法的建立 抑制剂(azt、ddi、ddC和3tc)将扩大到包括蛋白酶。 抑制剂(依地那韦、利托那韦、沙奎那韦和奈非那韦)和评价 使用临床样本。这项检测的结果将与 更昂贵的DNA测序方法和竞争的寡核苷酸连接 化验。 建议的商业应用：不可用

DESCRIPTION: (Adapted from Applicant's Abstract) Drug resistance is the single greatest reason for lack of HIV control. Quantitative measurements of viral load and drug resistance can provide the information necessary to rationally modify drug therapy. Increasing viral load can be caused by changes in the immunologic status of the patient or the virulence of the virus or by lack of patient compliance with the difficult drug scheduling. Treating patients who may have been infected with a drug resistant virus with combination drug therapy may be detrimental to the patient. Knowing the precise nature of a drug resistant mutation can also be used to predict cross-resistance or reduced resistance to other drugs. This work will develop RT-PCR conditions, primers, capture sequences, and internal standards that make quantitative detection of wild-type and drug-resistant HIV a simple and rapid process, even while accommodating the known sequence polymorphism found in the virus. In this Phase II study, the developed detection assay for the common reverse transcriptase inhibitors (AZT, ddI, ddC, and 3TC) will be expanded to include the protease inhibitors (indinavir, ritonavir, saquinavir, and nelfinavir) and evaluated using clinical samples. The results from this assay will be compared with the more costly DNA sequencing methods and a competing oligonucleotide ligation assay. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE